The efficacy of combination of temozolomide and capecitabine for neuroendocrine tumours: A real-world comparison of outcomes in Alberta, Canada – Patients treated from 2011-2021

#4384

Introduction: The combination of capecitabine and temozolomide (CAPTEM) showed PFS benefits in pancreatic neuroendocrine tumours (PNETs).

Aim(s): We aimed to assess its effectiveness in the broader NETs (neuroendocrine and endocrine tumours) population.

Materials and methods: We identified all patients with NETs treated with CAPTEM (at least 1 cycle) in Alberta from 2011-2021. PFS and OS from start of CAPTEM were compared between groups stratified by primary: Pancreatic NETs (PNETs); gastrointestinal NETs (GINETs); Pulmonary NETs (PuNET); other NETs (ONETs). PFS and OS were compared between NETs when CAPTEM was used as first vs. later-line therapy and patients receiving ≥ 6 vs. < 6 cycles.

Conference:

Presenting Author:

Authors: Aleksi A, Malek H, Husi P, Halperin H, White-Gloria C,

Keywords: captem, neuroendocrine tumour, endocrine tumour, progression-free survival, overall survival,